Skip to content
Whale Atlas — Follow the signal.
Home
FULL RECORDS
All Congress filingsSearch insider filingsEarnings calendarWatchlist
MORE TOOLS
Gold IntelligenceSilver IntelligencePeopleCharts & technicalsCompany financialsOfficial newsMy saved workspace
YOUR RESEARCH
HomeAll Congress filingsSearch insider filings
More research tools
ExploreGold IntelligenceSilver IntelligencePeopleInvestigate an ideaCharts & technicalsMore evidenceCompany financialsOfficial newsMy research & helpWatchlistMy saved workspaceLearn the basicsHow signals workData & coverage
RESOURCES
LearnMethodologyData sources
Built on public evidence.

Primary sources. Clear reasoning.
No black boxes.

Our approach
Public research workspacev1.0

Loading data…

CongressSearchHomeWatchlist
© 2026 Whale AtlasFree public-filing research. Not financial advice. By using this site you agree to the Terms of Use.
FAQCompare trackersMethodologyData & correctionsTermsPrivacy
LOOK INSIDE THE BUSINESS

Company financials.

Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.

View INBP insider activity ↗

INBPINTEGRATED BIOPHARMA INC

THE LATEST REPORTED YEAR

The company reported a loss.

$2.84M net loss for the year ended June 30, 2026. These are reported results, not a forecast or a stock recommendation.

Revenue$43.87MYear ended June 30, 2026
Profit or loss-$2.84MYear ended June 30, 2026
Cash from the business$1.24MYear ended June 30, 2026
Total assets$25.34MAs of June 30, 2026
Total liabilities$7.67MAs of June 30, 2026
Cash & equivalents$4.47MAs of June 30, 2026
THE BUSINESS BEHIND THE TICKER

Revenue, over time.

Latest-filed standard financial facts · USD

$49.98M
2019-06
$52.77M
2020-06
$63.56M
2021-06
$56.25M
2022-06
$50.67M
2023-06
$50.32M
2024-06
$54.35M
2025-06
$43.87M
2026-06

Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.

From the filing

Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.

Reported periodReported valueFiledSource
July 1, 2025 – June 30, 2026$43,872,000September 25, 202610-K ↗
July 1, 2024 – June 30, 2025$54,353,000September 25, 202610-K ↗
July 1, 2023 – June 30, 2024$50,317,000September 23, 202510-K ↗
July 1, 2022 – June 30, 2023$50,672,000September 20, 202410-K ↗
July 1, 2021 – June 30, 2022$56,246,000September 15, 202310-K ↗
July 1, 2020 – June 30, 2021$63,559,000September 13, 202210-K ↗
July 1, 2019 – June 30, 2020$52,769,000September 2, 202110-K ↗
July 1, 2018 – June 30, 2019$49,977,000September 23, 202010-K ↗
Source and calculation details

One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.

Concept: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · Retrieved October 14, 2026

Response SHA-256: 57e9ec38ed74f49823ff317c8f58dc34fd02eef4c16626537961ddbe96461aef

SEC company facts

Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.